CARsgen Therapeutics (2171.HK)

Executive Summary

CARsgen Therapeutics is a clinical-stage biopharmaceutical company pioneering CAR T-cell therapies for solid tumors and hematologic malignancies. Founded in 2014 and headquartered in Houston, the company trades on the Hong Kong Stock Exchange (2171.HK) with a valuation of ~$13.5 billion. Its pipeline includes autologous and allogeneic candidates targeting gastric cancer, multiple myeloma, and other solid tumors. Lead asset CT053 (autologous BCMA CAR T) is under regulatory review in China for relapsed/refractory multiple myeloma, while CT041 (autologous CLDN18.2 CAR T) has shown promising efficacy in gastric/gastroesophageal junction cancer. The company is advancing allogeneic programs to reduce manufacturing complexity and broaden patient access. Despite a competitive landscape, CARsgen's strong intellectual property and focus on hard-to-treat solid tumors position it as a key player in cell therapy innovation.

Upcoming Catalysts (preview)

• Q3 2026Potential NMPA approval decision for CT053 in multiple myeloma70% success
• Q4 2026Phase II data update for CT041 in gastric cancer60% success
• H1 2027Initiation of Phase I trial for allogeneic CAR T candidate50% success